# of Displayed Technologies: 10 / 63

Applied Category Filter (Click To Remove): Life & Health Sciences


Categories

Anti-GARP Monoclonal Antibodies for Cancer Therapy
TS-057778 — A novel monoclonal antibody (PIIO-1) to be used in combination with immune-checkpoint blockers. PIIO-1 augments CD8+ T cells-induced anti-tumor immunity and overcomes ICB resistance by disrupting transforming growth factor-β (TGF-β), the center of a pathway significantly implicated in solid tumors and hematological malignancies. PIIO-1 inhibits TGFβ locally via a docking receptor, avoiding adverse and unforeseen side effects.
Although immune checkpoint blockade (ICB) has emerged as a promising cancer immunotherapy, a majority of tumors fail to respond to ICB. A potential mechanism driving this failed response is the accumulation of TGF-β1 in the tumor microenvironment (TME), which drives immune dysfunction by indu…
  • College: College of Medicine (COM)
  • Inventors: Li, Zihai
  • Licensing Officer: He, Panqing

An Orally Active, Selective Inhibitor of CD4+ T-Cell Activation That Blunts Left-Ventricular Remodeling and Improves Cardiac Function during Chronic Heart Failure
TS-057777 — A novel orally-active drug molecule that can inhibit pathological CD4+ T-cells at clinically translatable doses and, blunts progressive cardiac dysfunction and left-ventricular (LV) remodeling during Heart Failure (HF).
HF afflicts ~6.5 million adults in US with 50% mortality in first 5 years. It has an estimated market size of $4.2B USD in US alone with a forecasted CAGR of 23% from 2018-2028. Current HF treatments are mostly aimed at alleviating symptoms rather than treatment, resulting in progressive cardiac d…
  • College: College of Medicine (COM)
  • Inventors: Bansal, Shyam; Gumina, Richard
  • Licensing Officer: He, Panqing

Albumin-SN-38 Conjugate (AlbuCure) for Cancer Therapy
TS-057776 — A novel protein-drug conjugate of human serum albumin chemically conjugated to SN-38, solubilizing the potent chemotherapeutic. This therapy has the potential to treat many tumors with poor prognosis, including pancreatic, lung, breast, colorectal, ovarian, sarcoma, head and neck cancer, urothelial malignancies, and others.
Many solid tumors have poor prognosis despite recent progress in molecularly targeted therapy and immunotherapy. Irinotecan/CPT-11, a chemotherapy on the WHO Essential Medicines List, is approved for use in colorectal cancer, lung cancer, pancreatic cancer, gastric cancer, malignant glioma, and sa…
  • College: College of Medicine (COM)
  • Inventors: Williams, Terence; Lee, Robert
  • Licensing Officer: He, Panqing

X-Ray Assistive Device for Standardizing the Knee Templating Process
TS-054471 — Knee templating is used as part of the pre-operative planning for knee replacement to determine the best fit for an implant. The current assistive devices used to determine fit are unreliable and inaccurate for proper patient fit. A new device is suggested to overcome these limitations.
Over 600,000 knee replacements are performed per year. As part of the pre-operative planning for surgery, x-ray images are taken to determine the proper fit for the implant. Even with the use of a calibration ball, this knee templating procedure remains inaccurate and unreliable for a number of re…
  • College: College of Engineering (COE)
  • Inventors: Ruegsegger, Mark; Aery, Dylan; Browske, Kimberly; Cantrell, Kaleb "Kaleb"; Reilman, Zach; Thew, Maddie
  • Licensing Officer: Zinn, Ryan

Therapeutic uses of the scavenging protein cocktail to treat plasma protein imbalances or depletion
TS-053103 — Uncontrolled hemolysis (i.e., destruction of red blood cells) is characterized by the increase of circulating toxic cell-free hemoglobin, heme and iron in the bloodstream. In vivo, the body’s natural supply of plasma scavenger proteins acts to neutralize these toxic species. However, these scavenger proteins such as haptoglobin, hemopexin and transferrin, which detoxify hemoglobin, heme and iron, respectively, are depleted in various clinical conditions such as hemorrhagic shock, burns, surgery, organ transplantation, sepsis and trauma. Dr. Andre Palmer’s lab at The Ohio State University has developed a novel therapeutic protein mixture, which can be used to treat plasma protein imbalances or depletion caused by the adverse events described above. The properties of this protein mixture are beneficial as they lend themselves to an inexpensive manufacturing process and potential improvements in clinical outcomes.
Fluid replacement as part of resuscitation efforts in clinical care is a cornerstone of treatment especially in cases with severe trauma. The regular usage of these fluids in hospitals requires the mixture to be easily transported, easily stored and applicable across a wide variety of patients. To…
  • College: College of Engineering (COE)
  • Inventors: Susin Pires, Ivan; Cabrales, Pedro; Palmer, Andre
  • Licensing Officer: Davis, Stewart

Novel Ergonomic Scalpel Handle
TS-051663 — Alleviate and prevent occupational stresses using this novel scalpel design.
A highly unfortunate outcome of the 2020 coronavirus pandemic is the over 400,000 American deaths that have unexpectedly overloaded medical autopsy services across the United States. With this heightened need for autopsy services previously unseen occupational hazards relating to repetitive motion…
  • College: College of Medicine (COM)
  • Inventors: Sachire, Jennifer
  • Licensing Officer: Schworer, Adam

Activation of human Argonaute3 (AGO3) using cityRNAs
TS-051298 — MicroRNAs (miRNAs) are small non-coding RNAs that control gene expression post-transcriptionally. Their sequences differ, but their lengths fall within a range of ~20-23 nucleotides because the precursor miRNAs are processed by Dicer. Dicer cleaves long double-stranded RNA (dsRNA) molecules into s…
  • College: College of Arts & Sciences
  • Inventors: Nakanishi, Kotaro; Park, Mi Seul
  • Licensing Officer: Willson, Christopher

Development of a live attenuated vaccine for leishmaniasis using CRISPR technology
TS-051167 — Methods of production and use of modified Leishmania species and compositions of live, attenuated organisms, immunogenic compositions, vaccines, and pharmaceutical compositions.
Leishmaniasis is a neglected tropical disease caused by infection with protozoans of the 15 genus Leishmania that is transmitted by infected sand flies. Worldwide, an estimated 1 billion people are at risk of infection in tropical and subtropical countries, with up to 1.7 million new cases in 98 c…
  • College: College of Medicine (COM)
  • Inventors: Satoskar, Abhay
  • Licensing Officer: Davis, Stewart

Novel acellular vaccine for protection against Bordetella infection
TS-050524 — Despite high vaccine coverage, whooping cough caused by Bordetella pertussis remains one of the most common vaccine-preventable diseases worldwide. Introduction of whole-cell pertussis (wP) vaccines in the 1940s and acellular pertussis (aP) vaccines in 1990s reduced mortality due to pertussis. Des…
  • College: College of Medicine (COM)
  • Inventors: Deora, Rajendar; Mishra, Meenu; Sukumar, Neelima
  • Licensing Officer: Schworer, Adam

Mini-PCDH15 for treatment of deafness
TS-050433 — A gene therapy solution for Usher Syndrome Type 1F.
Mutations in PCDH15 cause Usher 1F, a recessive syndrome characterized by profound congenital deafness and absence of vestibular function, and progressive blindness beginning in the second decade. Because patients who lack hearing and balance rely on vision for communication and mobility, the late…
  • College: College of Arts & Sciences
  • Inventors: Sotomayor, Marcos
  • Licensing Officer: Dahlman, Jason "Jay"

Show More Technologies

Loading icon